Clinical trial studies are now emerging based on the therapeutic inhibition of the histone methyltransferase EZH2, a key epigenetic regulator found to suppress the immunogenicity of tumour cells via transcriptional repression of genes involved in IFNγ response and antigen presentation [129]. This evidence concerns the gene EZH2 and neoplasm.